id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-N-0453-0051,FDA,FDA-2005-N-0453,"MEMORANDUM OF MEETING MINUTES - BASF Bemotrizinol and Bisoctrizole October 12, 2017",Other,Memorandum,2017-11-15T05:00:00Z,2017,11,2017-11-15T05:00:00Z,,2017-11-15T17:48:04Z,,0,0,0900006482c7b23a
FDA-2005-N-0453-0050,FDA,FDA-2005-N-0453,"Revision from BASF (Morgan, Lewis & Bockius LLP)",Other,Correction(s),2017-09-29T04:00:00Z,2017,9,2017-09-29T04:00:00Z,,2017-09-29T20:24:09Z,,0,0,0900006482b8cb9f
FDA-2005-N-0453-0049,FDA,FDA-2005-N-0453,Meeting Granted Letter BASF August 28 2017 Meeting Request,Other,Memorandum,2017-09-19T04:00:00Z,2017,9,2017-09-19T04:00:00Z,,2017-09-19T18:12:14Z,,0,0,0900006482b4f4e1
FDA-2005-N-0453-0048,FDA,FDA-2005-N-0453,"Meeting Materials from BASF (Morgan, Lewis & Bockius LLP)",Other,Meeting Exhibits,2017-09-12T04:00:00Z,2017,9,2017-09-12T04:00:00Z,,2017-09-29T20:24:44Z,,0,0,0900006482b2bf58
FDA-2005-N-0453-0047,FDA,FDA-2005-N-0453,"Request for Meeting from BASF (Morgan, Lewis & Bockius LLP)",Other,Request,2017-09-01T04:00:00Z,2017,9,2017-09-01T04:00:00Z,,2017-09-01T18:56:18Z,,0,0,0900006482b03dc4